.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Teva
Boehringer Ingelheim
Harvard Business School
McKesson
Cerilliant
Merck
Express Scripts
Fish and Richardson
Cipla

Generated: December 14, 2017

DrugPatentWatch Database Preview

Details for Patent: ► Subscribe

« Back to Dashboard

Details for Patent: ► Subscribe

Title: Adenosine A3 receptor modulators
Abstract:The compounds of formula I wherein R, R.sup.1, R.sup.2 R.sup.3 and A have the meanings given in the specification, are endowed with selective A.sub.3 adenosine receptor agonist activity. These compounds can be used in a pharmaceutical composition to treat disorders caused by excessive activation of the A.sub.3 receptor, or can be used in a diagnostic application to determine the relative binding of other compounds to the A.sub.3 receptor.
Inventor(s): Baraldi; Pier Giovanni (Ferrara, IT)
Assignee: King Pharmaceuticals Research and Development, Inc. (Cary, NC)
Filing Date:Sep 16, 1998
Application Number:09/154,435
Claims:1. A compound of the following formula: ##STR17##

wherein: A is imidazole, pyrazole, or triazole; R is --C(X)R.sup.1, --C(X)--N(R.sup.1).sub.2, --C(X)OR.sup.1, --C(X)SR.sup.1, --SO.sub.n --R.sup.1, --SO.sub.n OR.sup.1, --SO.sub.n --SR.sup.1, or SO.sub.n --N(R.sup.1).sub.2 ; R.sup.1 is hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, heteroaryl, heterocyclic, lower alkenyl, lower alkanoyl, or, if linked to a nitrogen atom, then taken together with the nitrogen atom, forms an azetidine ring or a 5-6 membered heterocyclic ring containing one or more heteroatoms; R.sup.2 is hydrogen, alkyl, substituted alkyl, aralkyl, substituted aralkyl, heteroaryl, substituted heteroaryl or aryl; R.sup.3 is furan, pyrrole, thiophene, benzofuran, benzopyrrole, benzothiophene, optionally substituted with one or more substituents selected from the group consisting of hydroxy, acyl, alkyl, alkoxy, alkenyl, alkynyl, substituted alkyl, substituted alkoxy, substituted alkenyl, substituted alkynyl, amino, substituted amino, aminoacyl, acyloxy, acylamino, alkaryl, aryl, aryloxy, azido, carboxyl, carboxylalkyl, cyano, halo, nitro, heteroaryl, heteroaryloxy, heterocyclic, heterocyclooxy, aminoacyloxy, thioalkoxy, substituted thioalkoxy, thioaryloxy, thioheteroaryloxy, --SO-alkyl, --SO-substituted alkyl, --SO-aryl, --SO-heteroaryl, --SO.sub.2 -alkyl, --SO.sub.2 -substituted alkyl, --SO.sub.2 -aryl, --SO.sub.2 -heteroaryl, and trihalomethyl; X is O, S, or NR.sup.1 ; n is 1 or 2; and pharmaceutically acceptable salts thereof.

2. The compound of claim 1 wherein R is --C(X)R.sup.1, --C(X)--N(R.sup.1).sub.2, --SO.sub.n R.sup.1 or --SO.sub.n --N(R.sup.1).sub.2 wherein X is O or S.

3. The compound of claim 1 wherein R.sup.1 is selected from the group consisting of hydrogen, alkyl, alkenyl and aryl.

4. The compound of claim 1 wherein R.sup.2 is selected from the group consisting of hydrogen, alkyl and aryl.

5. The compound of claim 1 wherein R.sup.3 is furan.

6. The compound of claim 1 wherein X is O.

7. The compound of claim 1 wherein A is a triazolo ring.

8. The compound of claim 1 wherein A is a pyrazolo ring.

9. A method of treating hypertension, inflammation, allergic reactions, mast cell degranulation, and cardiac hypoxia, and protecting against cerebral ischemia, comprising administering to a patient in need of treatment thereof an effective amount of a compound of claim 1.

10. The method of claim 9 wherein R is --C(X)R.sup.1, --C(X)--N(R.sup.1).sub.2, --SO.sub.n R.sup.1 or --SO.sub.n --N(R.sup.1).sub.2 wherein X is O or S.

11. The method of claim 9 wherein R.sup.1 is selected from the group consisting of hydrogen, alkyl, alkenyl and aryl.

12. The method of claim 9 wherein R.sup.2 is selected from the group consisting of hydrogen, alkyl and aryl.

13. The method of claim 9 wherein X is O.

14. The method of claim 9 wherein A is a pyrazolo ring.

15. The method of claim 9 wherein A is a triazolo ring.

16. The method of claim 9 wherein the disorder to be treated is selected from the group consisting of cardiac hypoxia and cerebral ischemia.

17. A compound selected from the group of compounds consisting of: 5-[[(3-Chlorophenyl)amino]carbonyl]amino-8-methyl-2-(2-furyl)-pyrazolo[4,3- e]-1,2,4-triazolo[1,5-c]pyrimidine, 5-[[(4-Methoxyphenyl)amino]carbonyl]amino-8-methyl-2-(2-furyl)-pyrazolo[4,3 -e]-1,2,4-triazolo[1,5-c]pyrimidine, 5-[[(3-Chlorophenyl)amino]carbonyl]amino-8-ethyl-2-(2-furyl)-pyrazolo[4,3-e ]-1,2,4-triazolo[1,5-c]pyrimidine, 5-[[(4-Methoxyphenyl)amino]carbonyl]amino-8-ethyl-2-(2-furyl)-pyrazolo[4,3- e]-1,2,4-triazolo[1,5-c]pyrimidine, 5-[[(3-Chlorophenyl)amino]carbonyl]amino-8-propyl-2-(2-furyl)-pyrazolo[4,3- e]-1,2,4-triazolo[1,5-c]pyrimidine, 5-[[(4-Methoxyphenyl)amino]carbonyl]amino-8-propyl-2-(2-furyl)-pyrazolo[4,3 -e]-1,2,4-triazolo[1,5-c]pyrimidine, 5-[[(3-Chlorophenyl)amino]carbonyl]amino-8-butyl-2-(2-furyl)-pyrazolo[4,3-e ]-1,2,4-triazolo[1,5-c]pyrimidine, 5-[[(4-Methoxyphenyl)amino]carbonyl]amino-8-butyl-2-(2-furyl)-pyrazolo[4,3- e]-1,2,4-triazolo[1,5-c]pyrimidine, 5-[[(3-Chlorophenyl)amino]carbonyl]amino-8-isopentyl-2-(2-furyl)-pyrazolo[4 ,3-e]-1,2,4-triazolo[1,5-c]pyrimidine, 5-[[(4-Methoxyphenyl)amino]carbonyl]amino-8-isopentyl-2-(2-furyl)-pyrazolo[ 4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine, 5-[[(3-Chlorophenyl)amino]]carbonyl]amino-8-(2-isopentenyl)-2-(2-furyl)pyra zolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidine, 5-[[(4-Methoxyphenyl)amino]carbonyl]amino-8-(2-isopentenyl)-2-(2-furyl)-pyr azolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine, 5-[[(3-Chlorophenyl)amino]carbonyl]amino-8-(2-phenylethyl)-2 (2-furyl)-pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine, 5-[[(4-Methoxyphenyl)amino]carbonylamino-8-(2-phenylethyl)-2-(2-furyl)-pyra zolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine, 5-[[(3-Chlorophenyl)amino]carbonyl]amino-8-(3-phenylpropyl)-2-(2-furyl)-pyr azolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine, 5-[[(4-Methoxyphenyl)amino]carbonyl]amino-8-(3-phenylpropyl)-2-(2-furyl)-py razolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine, 5-[(Benzyl)carbony]amino-8-isopentyl-2-(2-furyl)-pyrazolo[4,3-e]-1,2,4-tria zolo[1,5-c]pyrimidine, and 5-[(Benzyl)carbonyl]amino-8-(3-phenylpropyl)-2-(2-furyl)-pyrazolo[4,3-e]-1, 2,4-triazolo[1,5-c]pyrimidine.

18. A method of treating hypertension, inflammation, allergic reactions, mast cell degranulation and cardiac hypoxia, and protecting against cerebral ischemia, comprising administering to a patient in need of treatment thereof an effective amount of a compound of claim 17.

19. A compound selected from the group of compounds consisting of: 5-[[(3-Chlorophenyl)amino]]carbonyl]amino-8-(2-isopentenyl)-2-(2-furyl)pyra zolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidine, and 5-[[(4-Methoxyphenyl)amino]carbonyl]amino-8-(2-isopentenyl)-2-(2-furyl)-pyr azolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine.
« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Dow
Chinese Patent Office
Moodys
Fuji
Argus Health
Queensland Health
Fish and Richardson
UBS
Teva
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot